Urogen Pharma (URGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $35.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tara Bancroft has given her Buy rating due to a combination of factors related to Urogen Pharma’s promising developments. The anticipation of a positive outcome from the upcoming ODAC meeting on May 21st is expected to address any lingering concerns with strong real-world perspectives. The company is optimistic about receiving timely approval, as the review team remains consistent and the Agency has confirmed its commitment to the planned schedule.
Additionally, while Q1 Jelmyto sales were slightly below expectations, the year-over-year growth is projected to continue, with management forecasting a significant increase in revenue by 2025. The likelihood of UGN-102’s approval is high, supported by favorable Phase III data and expert opinions. The FDA’s acceptance of the NDA and the set PDUFA date further strengthen the case for approval, which is anticipated to be a significant positive catalyst for the company.
In another report released on April 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.